NEW DELHI: Pharma major Cipla is expected to report a 25-27 per cent year-on-year (YoY) rise in profit for December quarter. PhillipCapital expects the drug maker to report 26.9 per cent rise in profit at Rs 421 crore. Sequentially, it sees profit falling 11 per cent. “Cipla is likely to report modest sales growth due to declining sales from gSensipar in the US and muted domestic performance,” it said. We expect South Africa to decline 1 per cent YoY, and expect Global Access, EU and RoW to grow at 5 per cent, 22 per cent and 9 per cent YoY, respectively,” it said.

Source: Economic Times February 05, 2020 07:05 UTC